AKRO

Q3 '20

Last Updated:

Akero Therapeutics

Our mission is to reverse the course of serious metabolic diseases and transform patients’ lives. Our dedicated team is laser-focused on reversing the NASH epidemic by restoring the body’s metabolism to a balanced state.

Cash

$291.9M

Burn Rate (Quarterly)

$21.4M

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

Efruxifermin (AKR-001)

Non-alcoholic Steatohepatitis (NASH)

Phase 2a readout

H1 2020

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon